Ajanta Pharma will hold a meeting of the Board of Directors of the Company on 30 July 2020.

Powered by Capital Market - Live News

Ajanta Pharma announced that the 41th Annual General Meeting (AGM) of the company will be held on 30 July 2020.

Powered by Capital Market - Live News

Bayer CropScience Ltd, New India Assurance Company Ltd, Aurobindo Pharma Ltd and Petronet LNG Ltd are among the other losers in the BSE's 'A' group today, 01 June 2020.

Ajanta Pharma Ltd lost 4.80% to Rs 1450.5 at 14:53 IST.The stock was the biggest loser in the BSE's 'A' group.On the BSE, 16469 shares were traded on the counter so far as against the average daily volumes of 9972 shares in the past one month.

Bayer CropScience Ltd tumbled 3.63% to Rs 5179.95. The stock was the second biggest loser in 'A' group.On the BSE, 2460 shares were traded on the counter so far as against the average daily volumes of 2903 shares in the past one month.

New India Assurance Company Ltd crashed 3.11% to Rs 116.8. The stock was the third biggest loser in 'A' group.On the BSE, 22654 shares were traded on the counter so far as against the average daily volumes of 20350 shares in the past one month.

Aurobindo Pharma Ltd corrected 3.01% to Rs 722.65. The stock was the fourth biggest loser in 'A' group.On the BSE, 1.09 lakh shares were traded on the counter so far as against the average daily volumes of 2.91 lakh shares in the past one month.

Petronet LNG Ltd pared 2.85% to Rs 246.8. The stock was the fifth biggest loser in 'A' group.On the BSE, 85555 shares were traded on the counter so far as against the average daily volumes of 73115 shares in the past one month.

Powered by Capital Market - Live News

Profit before tax (PBT) rose 61.06% to Rs 175.86 crore in Q4 March 2020 over Q4 March 2019. Current tax expense jumped 272.97% to Rs 49.53 crore during the quarter. Consolidated EBITDA grew at 19% to Rs 151 crore in Q4 March 2020 over Q4 March 2019.

During the quarter, India sales were up 11% to Rs 177 crore in Q4 March 2020 as compared to Rs 159 crore in Q4 March 2019. As per IQVIA MAT March 2020, the company posted a healthy growth of 11% in Cardiology (segment growth of 11%), 17% in Ophthalmology (segment growth of 11%), 6% in Dermatology (segment growth of 9%) and 16% in Pain Management (segment growth of 12%).

Total exports soared 43% to Rs 490 crore in Q4 March 2020 from Rs 343 crore in Q4 March 2019. The pharma company's emerging market branded generic sale surged 38% year-on-year basis to Rs 304 crore in Q4 March 2020. US generic sale stood at 143 crore, recording a sensational growth of 88% on year on year basis in Q4 March 2020.

The company said R&D expenses were at Rs 50 crore in Q4 March 2020, (Q4 FY 2019 Rs 40 crore) which is 7% of operating revenue.

Ajanta Pharma's consolidated net profit surged 21% to Rs 467.70 crore on 25.9% rise in net sales to Rs 2587.87 crore in the year ended March 2020 (FY20) over the year ended March 2019 (FY19). PBT rose 29.11% to 663.97 crore in FY20 over FY19.

Ajanta Pharma is a specialty pharmaceutical company engaged in developing, producing and marketing a range of branded and generic formulations.

Powered by Capital Market - Live News